These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14717986)

  • 21. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P
    Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C.
    Hsu CS; Kao JH
    N Engl J Med; 2009 Oct; 361(18):1808-9; author reply 1809. PubMed ID: 19864682
    [No Abstract]   [Full Text] [Related]  

  • 25. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 28. [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Izumi N; Kurosaki M; Suzuki S; Tamaki N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2108-11. PubMed ID: 23221060
    [No Abstract]   [Full Text] [Related]  

  • 29. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
    Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
    Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Nishiofuku M; Tsujimoto T; Matsumura Y; Toyohara M; Yoshiji H; Yamao J; Fukui H; Yoshikawa M
    Intern Med; 2006; 45(7):483-4. PubMed ID: 16679707
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.
    Tan AC; Brouwer JT; Glue P; van Leusen R; Kauffmann RH; Schalm SW; de Vries RA; Vroom B
    Nephrol Dial Transplant; 2001 Jan; 16(1):193-5. PubMed ID: 11209032
    [No Abstract]   [Full Text] [Related]  

  • 34. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
    August-Jörg BS; Borovicka J; Dufour JF; Gonvers JJ; Henz S; Hermann R; Meyenberger C; Weitz M; Renner EL;
    Swiss Med Wkly; 2003 Aug; 133(33-34):455-60. PubMed ID: 14625812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
    Verbaan HP; Widell HE; Bondeson TL; Lindgren SC;
    Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):627-33. PubMed ID: 12072596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.
    Sievert W; Batey R; Mollison L; Pianko S; McDonald J; Marinos G; Reed W; Warner S; Bowden S; De Solom R; Bhathal P;
    Aliment Pharmacol Ther; 2003 May; 17(9):1197-204. PubMed ID: 12752357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
    Hiramatsu N
    Nihon Naika Gakkai Zasshi; 2008 Jan; 97(1):75-81. PubMed ID: 18360974
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.
    Malik AH; Kumar KS; Malet PF; Ostapowicz G; Adams G; Wood M; Yarbrough K; Jones A; Lee WM
    Aliment Pharmacol Ther; 2002 Mar; 16(3):381-8. PubMed ID: 11876690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.